BLTE earnings date and last-quarter result: next report 2026-08-10, last quarter beat, P/E -61.62. Updated 2026-07-23.
Belite Bio (BLTE) Research Hub
Belite Bio (BLTE) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 143.35 USD (-2.70%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -61.62, market cap 6.26B. This hub links to the full technical, earnings and options research available for BLTE.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 143.35 USD (-2.70%) |
| 52-week range | 136.15 USD – 198.58 USD |
| Trend regime | Range |
| 14-day RSI | 37.8 (Bearish) |
| Trailing P/E | -61.62 |
| Market cap | 6.26B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for BLTE
Covered Call on BLTE: how it works, illustrative setup around the real 143.35 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on BLTE: how it works, illustrative setup around the real 143.35 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on BLTE: how it works, illustrative setup around the real 143.35 USD price, max profit/loss, breakeven and when to use it. Educational.
BLTE technical analysis: range, last 143.35 USD, RSI 37.8, 52w range 136.15 USD–198.58 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is BLTE in?
Belite Bio (BLTE) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is BLTE in an uptrend or downtrend?
As of 2026-10-26, BLTE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is BLTE's trailing P/E ratio?
BLTE's trailing P/E is -61.62, with a market cap of 6.26B. See the earnings research page for full valuation detail.
When does BLTE next report earnings?
BLTE is next scheduled to report earnings on 2026-08-10.